Sanofi licenses novel monoclonal from Glenmark for up to $663 million
This article was originally published in Scrip
In a significant move that may switch the image of India in biologics from a follower to a leader, Glenmark Pharmaceuticals has granted French drugs giant Sanofi a licence for the development and commercialisation of a novel monoclonal antibody for the treatment of Crohn's disease and other chronic autoimmune conditions. The deal involves a $50 million up front payment to Glenmark.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.